AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9143859
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of antimalarials
Trial: 2960473
Drug: Enoximone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (150 mg tid for 6 weeks)
Trial: 31389201
Drug: Trelagliptin 25
RxNorm normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Trelagliptin 25 mg
Trial: 29401258
Drug: Orthonasal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthonasal delivery of linalool (12%) at 6 L/min
Trial: 29401258
Drug: Orthonasal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthonasal delivery of vanillin (25%) at 6 L/min
Trial: 29401258
Drug: Retronasal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retronasal delivery of linalool (12%) at 8 L/min
Trial: 29401258
Drug: Retronasal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retronasal delivery of vanillin (25%) at 8 L/min
Trial: 18256431
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) for lymphatic filariasis, administered annually for four years.
Trial: 16109592
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day) for 14 weeks
Trial: 12520627
Drug: Reduced-dose probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose probenecid (RDP) 2 g at 1 hour before cidofovir
Trial: 12520627
Drug: Standard-dose probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose probenecid (SDP) 2 g at 3 hours before cidofovir, then 1 g at 2 and 8 hours after cidofovir
Trial: 12520627
Drug: Cidofovir 5
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cidofovir 5 mg/kg as a 1-hour infusion after saline prehydration
Trial: 10799813
Drug: Paracetamol tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol tablet with sodium bicarbonate (630 mg)
Trial: 10799813
Drug: Paracetamol tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol tablet with sodium bicarbonate (400 mg)
Trial: 10799813
Drug: Paracetamol tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol tablet with calcium carbonate (375 mg)
Trial: 10799813
Drug: Conventional paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional paracetamol tablet (500 mg)
Trial: 10799813
Drug: Soluble paracetamol
RxNorm normalized name: Disprol Soluble Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble paracetamol tablet
Trial: 8780277
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 12.5 mg bupivacaine plus saline (SS)
Trial: 1610577
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg IV
Trial: 1610577
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 2 ml IV)
Trial: 6386936
Drug: Intranasal fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fenoterol (0.2 mg in each nostril, total 0.8 mg)
Trial: 6386936
Drug: Oral fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenoterol (0.4 mg inhalation)
Trial: 6386936
Drug: Intranasal fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fenoterol
Trial: 31837238
Drug: Ordinal outcomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinal outcomes based on baseline platelet count (cutoff, 150 × 10^9/L)
Trial: 30026000
Drug: Niraparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (300 mg once daily)
Trial: 28683357
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (16-week, 3 times per week of heart rate guided-aerobic plus resistance training)
Trial: 21436683
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and ketamine (MK)
Trial: 21436683
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and saline (MS)
Trial: 19766399
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel (Scarfade)
Trial: 19766399
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheet (Epi-Derm)
Trial: 19766399
Drug: Topical onion
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical onion extract including heparin and allantoin (Contractubex)
Trial: 11429022
Drug: Preemptive ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive ganciclovir treatment for asymptomatic infection
Trial: 24498368
Drug: Nordic FLOX
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy
Trial: 24498368
Drug: Updated plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Updated plasma YKL‐40 levels after treatment
Trial: 20739874
Drug: Marine collagen
RxNorm normalized name: marine collagen, soluble
DrugBank: Marine collagen, soluble (DB14246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine collagen peptides (MCPs) treatment
Trial: 17665470
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and directed exercise
Trial: 7009441
Drug: Carprofen stepwise
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen stepwise 150, 200, and 250 mg/day
Trial: 7009441
Drug: Carprofen 350,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen 350, 400, and 450 mg/day
Trial: 7009441
Drug: Carprofen low
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen low dosage regimen
Trial: 31196016
Drug: Carglumic acid
RxNorm normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carglumic acid (50 mg/kg/day) plus standard therapy (protein-restricted diet, L-carnitine, and metronidazole)
Trial: 31196016
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (protein-restricted diet, L-carnitine, and metronidazole)
Trial: 21071558
Drug: EPO therapy
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO therapy (50 IU/kg/wk) for 52 weeks
Trial: 21071558
Drug: No EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No EPO therapy (control group)
Trial: 18536953
Drug: Alendronate 280
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 280 mg once-weekly oral buffered solution (OW OBS)
Trial: 18536953
Drug: Alendronate 40
RxNorm normalized name: ALENDRONATE 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 40 mg/day tablet
Trial: 11797178
Drug: Protease Inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease Inhibitor (group C)
Trial: 28490349
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) intervention consisting of one 60-minute session and seven 30-minute telephone/Skype sessions over an eight-week period.
Trial: 23698243
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection (0.5 mL dexamethasone suspension and 3 mL lidocaine)
Trial: 23698243
Drug: Palpation-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided injection (0.5 mL dexamethasone suspension and 3 mL lidocaine)
Trial: 19052293
Drug: combination (comb)
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination (comb)
Trial: 14964327
Drug: Sound field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sound field FM amplification (SFA) in treatment group classrooms
Trial: 10194143
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms fenoterol‐80 micrograms ipratropium bromide (four puffs) from a metered‐dose inhaler (MDI)
Trial: 10194143
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg fenoterol‐500 micrograms ipratropium bromide in 5 ml saline from a nebulizer (NEB)
Trial: 2181040
Drug: Various combinations
RxNorm normalized name: various combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various combinations of existing antileprosy drugs administered for 5 years to new untreated patients (Group I) and relapsed patients (Group II)
Trial: 2181040
Drug: Clofazimine (even
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine (even in low doses)
Trial: 31253441
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis (baseline Lp(a) ≥50 mg/dL)
Trial: 21960156
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg levobupivacaine in 60 mL 0.9% saline
Trial: 21960156
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL 0.9% saline (placebo)
Trial: 17466722
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (30 minutes per day, 5 days a week for 4 weeks)
Trial: 9787543
Drug: Antimicrobial oral
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial oral rinse (0.12 percent chlorhexidine)
Trial: 19855209
Drug: Continuous lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous lateral rotational therapy
Trial: 11737740
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose nebulized albuterol therapy (0.15 mg/kg)
Trial: 11737740
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose nebulized albuterol (0.075 mg/kg) plus nebulized ipratropium bromide therapy (250 microg/dose)
Trial: 9422890
Drug: Ropivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Trial: 9422890
Drug: Bupivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Trial: 12959320
Drug: Minaprine 100
RxNorm normalized name: minaprine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine 100 mg
Trial: 2827471
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus sulindac (200 mg BID)
Trial: 2827471
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus indomethacin (50 mg BID)
Trial: 25015066
Drug: Late remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late remote ischemic preconditioning (L‐RIPC)
Trial: 17971112
Drug: MOD preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD preparation restored with composite resin (Z‐250, 3M ESPE)
Trial: 17971112
Drug: MOD preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD preparation and endodontic treatment
Trial: 17971112
Drug: MOD preparation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD preparation, endodontic treatment, and composite resin restoration
Trial: 17971112
Drug: MOD preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD preparation
Trial: 15957693
Drug: 9.0 mg
RxNorm normalized name: NITROGLYCERIN 9.0 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.0 mg glucose-free bupivacaine with added fentanyl 20 microg (group BF)
Trial: 15957693
Drug: 11.0 mg
RxNorm normalized name: ZINC OXIDE 11.0 mg in 100 mL / TITANIUM DIOXIDE 6.2 mg in 100 mL TOPICAL LOTION [Yes To Cucumbers Daily Moisturizer SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.0 mg glucose-free bupivacaine alone (group B)
Trial: 7564346
Drug: UP269-6 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP269-6 (doses ranging from 5 to 180 mg)
Trial: 7564346
Drug: UP269-6 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP269-6 (20 mg and 40 mg)
Trial: 1767900
Drug: Thick layer
RxNorm normalized name: Bayer Aspirin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thick layer of lignocaine-prilocaine cream (2.0 ml)
Trial: 1767900
Drug: Thin layer
RxNorm normalized name: Bayer Aspirin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin layer of lignocaine-prilocaine cream (0.5 ml)
Trial: 6951009
Drug: High-calorie dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie dietary supplement providing a minimum of 50% of energy requirements
Trial: 28411244
Drug: Drug-Eluting Stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stents (DESs) with paclitaxel
Trial: 22433279
Drug: Aciclovir 400
RxNorm normalized name: Aciclovir 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aciclovir 400 mg orally twice daily
Trial: 19727537
Drug: Trospium ER
RxNorm normalized name: trospium Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium ER 60 mg once daily for 12 weeks
Trial: 7875148
Drug: GM‐CSF, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF, 5 micrograms/kg daily (intravenously or subcutaneously) for ten days
Trial: 23361871
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication for first 3 months, then bosentan for 6 months)
Trial: 17894257
Drug: Treatment participants
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment participants received a series of mailed materials and two educational calls over 6 months.
Trial: 9849179
Drug: Increased oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased oral fluid intake
Trial: 7852747
Drug: corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corn oil (4 capsules of 1g/day)
Trial: 30240132
Drug: CSL112 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 2 g
Trial: 28790038
Drug: ParticiPAte CP
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ParticiPAte CP (participation focused therapy)
Trial: 22276690
Drug: Immediate placement
RxNorm normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate placement of wide-diameter implants in fresh molar extraction sockets
Trial: 22276690
Drug: Delayed placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed placement of wide-diameter implants in healed sites
Trial: 22276690
Drug: Immediately placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediately placed implants
Trial: 22276690
Drug: Delayed placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed placed implants
Trial: 21498904
Drug: Cognitive intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive intervention group (IG) receiving weekly sessions of group‐based multicomponent cognitive intervention.
Trial: 18574688
Drug: Three‐way combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three‐way combination of GSTP1 105AA/AG and null genotypes for both GSTM1 and GSTT1
Trial: 11922398
Drug: Troxerutin 150
RxNorm normalized name: troxerutin
DrugBank: Troxerutin (DB13124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troxerutin 150 mg and carbazochrome 1.5 mg
Trial: 9517631
Drug: Foscarnet 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet 90 mg/kg b.i.d. for 21 days
Trial: 9517631
Drug: Ganciclovir 5
RxNorm normalized name: ganciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 5 mg/kg b.i.d. for 21 days
Trial: 8299789
Drug: CC-stimulated, hCG-timed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-stimulated, hCG-timed IUI
Trial: 2680583
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg protriptyline
Trial: 2680583
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg protriptyline
Trial: 786204
Drug: Imipramine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 300 mg daily
Trial: 786204
Drug: Imipramine 150
RxNorm normalized name: imipramine pamoate 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 150 mg daily
Trial: 31063575
Drug: Aclidinium (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium (400 μg twice daily)
Trial: 19918595
Drug: Local antibiotics
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antibiotics (two groups with proven efficacy)
Trial: 10618679
Drug: G(-6)A genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G(-6)A genotype
Trial: 24305422
Drug: Novel hydroxyphenoxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel hydroxyphenoxy propionic acid, ellagic acid, yeast extract, and salicylic acid formulation applied twice daily
Trial: 24305422
Drug: Standard prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prescription combination of 4% hydroquinone cream and 0.025% tretinoin cream applied nightly
Trial: 24305422
Drug: Both products
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both products (novel formulation and prescription combination)
Trial: 1544585
Drug: Low-dose antihypertensive
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antihypertensive medication (chlorthalidone)
Trial: 18549463
Drug: PEG‐IFN alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alfa‐2b 1.0 micro/kg/week plus RBV 8‐10 mg/kg/day for 24 weeks (group A)
Trial: 15852629
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (6.17 +/- 0.98 mg x kg(‐1) x h(‐1)) after delivery
Trial: 14592306
Drug: Oral interface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral interface (Oracle)
Trial: 8568290
Drug: RRV‐TV (tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV‐TV (tetravalent rhesus-human rotavirus vaccine)
Trial: 8568290
Drug: RRV‐S1 (monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV‐S1 (monovalent rhesus-human rotavirus vaccine)
Trial: 8568290
Drug: Rotavirus vaccines
RxNorm normalized name: Rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavirus vaccines (both RRV‐S1 and RRV‐TV)
Trial: 1658700
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (0.625 and 1.25 mg)
Trial: 7056949
Drug: RW-Cl (clustered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RW-Cl (clustered doses of ragweed extract at 3-wk intervals)
Trial: 7056949
Drug: RW-Wk (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RW-Wk (weekly injections of single doses of ragweed extract)
Trial: 7056949
Drug: Rinkel-method immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinkel-method immunotherapy
Trial: 31502662
Drug: Monopolar radiofrequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monopolar radiofrequency device with single microneedle, 3 treatments at 4-week intervals
Trial: 30076270
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day donepezil (in apolipoprotein ϵ 4 non-carriers)